CN101618069A - 一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 - Google Patents
一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 Download PDFInfo
- Publication number
- CN101618069A CN101618069A CN200910203675A CN200910203675A CN101618069A CN 101618069 A CN101618069 A CN 101618069A CN 200910203675 A CN200910203675 A CN 200910203675A CN 200910203675 A CN200910203675 A CN 200910203675A CN 101618069 A CN101618069 A CN 101618069A
- Authority
- CN
- China
- Prior art keywords
- medical material
- preferred
- radix notoginseng
- resin
- material amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 239000002775 capsule Substances 0.000 title claims abstract description 39
- 230000000740 bleeding effect Effects 0.000 title abstract description 19
- 230000036407 pain Effects 0.000 title abstract description 9
- 208000034656 Contusions Diseases 0.000 title abstract 3
- 208000034526 bruise Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 79
- 239000003814 drug Substances 0.000 claims abstract description 64
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 24
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 24
- 229920002472 Starch Polymers 0.000 claims abstract description 18
- 239000008107 starch Substances 0.000 claims abstract description 18
- 235000019698 starch Nutrition 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 374
- 239000012567 medical material Substances 0.000 claims description 125
- 239000011347 resin Substances 0.000 claims description 125
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 110
- 241000180649 Panax notoginseng Species 0.000 claims description 110
- 229920005989 resin Polymers 0.000 claims description 109
- 238000010828 elution Methods 0.000 claims description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 97
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 90
- 239000000284 extract Substances 0.000 claims description 89
- 239000007788 liquid Substances 0.000 claims description 48
- 229910021529 ammonia Inorganic materials 0.000 claims description 45
- 208000032843 Hemorrhage Diseases 0.000 claims description 29
- 238000001035 drying Methods 0.000 claims description 29
- 239000012141 concentrate Substances 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 17
- 239000003480 eluent Substances 0.000 claims description 16
- 206010030113 Oedema Diseases 0.000 claims description 11
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 10
- 238000012856 packing Methods 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 abstract description 41
- 235000002789 Panax ginseng Nutrition 0.000 abstract 3
- 241001191006 Phlomoides rotata Species 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 78
- 238000000605 extraction Methods 0.000 description 55
- 239000000243 solution Substances 0.000 description 48
- 239000003463 adsorbent Substances 0.000 description 30
- 238000001179 sorption measurement Methods 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 239000000203 mixture Substances 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000037396 body weight Effects 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 235000008504 concentrate Nutrition 0.000 description 19
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 19
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 19
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 19
- 235000009498 luteolin Nutrition 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 239000013558 reference substance Substances 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 239000012535 impurity Substances 0.000 description 14
- 239000013642 negative control Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- -1 reflux Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 238000003304 gavage Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000003032 molecular docking Methods 0.000 description 12
- 229930182490 saponin Natural products 0.000 description 12
- 150000007949 saponins Chemical class 0.000 description 12
- 235000017709 saponins Nutrition 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 230000000274 adsorptive effect Effects 0.000 description 11
- 238000011835 investigation Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 10
- 238000012449 Kunming mouse Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 238000003809 water extraction Methods 0.000 description 9
- 239000013641 positive control Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000009306 yunnan baiyao Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000002203 pretreatment Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 238000003795 desorption Methods 0.000 description 5
- 238000002481 ethanol extraction Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 102000003712 Complement factor B Human genes 0.000 description 4
- 108090000056 Complement factor B Proteins 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000238370 Sepia Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- MQJQTJJSIQAMNI-UHFFFAOYSA-N C(CO)O.O.C1(C(C(C2=CC=CC=C12)=O)=O)=O Chemical compound C(CO)O.O.C1(C(C(C2=CC=CC=C12)=O)=O)=O MQJQTJJSIQAMNI-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- DBJUEJCZPKMDPA-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O DBJUEJCZPKMDPA-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000007728 cost analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102036755A CN101618069B (zh) | 2009-06-15 | 2009-06-15 | 一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102036755A CN101618069B (zh) | 2009-06-15 | 2009-06-15 | 一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101618069A true CN101618069A (zh) | 2010-01-06 |
CN101618069B CN101618069B (zh) | 2012-01-04 |
Family
ID=41511597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102036755A Active CN101618069B (zh) | 2009-06-15 | 2009-06-15 | 一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101618069B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103705571A (zh) * | 2013-12-27 | 2014-04-09 | 成都九芝堂金鼎药业有限公司 | 一种止血镇痛胶囊及其制备方法 |
CN109045116A (zh) * | 2018-09-11 | 2018-12-21 | 江苏七0七天然制药有限公司 | 一种胃药胶囊及其制备方法 |
CN109316543A (zh) * | 2018-10-22 | 2019-02-12 | 江苏七0七天然制药有限公司 | 一种复方元胡止痛胶囊及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1583043A (zh) * | 2004-06-07 | 2005-02-23 | 刘梅 | 一种独一味提取物和它的制备工艺及其应用 |
CN1961912B (zh) * | 2005-11-11 | 2010-05-05 | 成都优他制药有限责任公司 | 一种具有镇痛止血作用的中药组合物 |
-
2009
- 2009-06-15 CN CN2009102036755A patent/CN101618069B/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103705571A (zh) * | 2013-12-27 | 2014-04-09 | 成都九芝堂金鼎药业有限公司 | 一种止血镇痛胶囊及其制备方法 |
CN103705571B (zh) * | 2013-12-27 | 2016-08-17 | 成都九芝堂金鼎药业有限公司 | 一种止血镇痛胶囊及其制备方法 |
CN109045116A (zh) * | 2018-09-11 | 2018-12-21 | 江苏七0七天然制药有限公司 | 一种胃药胶囊及其制备方法 |
CN109316543A (zh) * | 2018-10-22 | 2019-02-12 | 江苏七0七天然制药有限公司 | 一种复方元胡止痛胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101618069B (zh) | 2012-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102988526B (zh) | 一种白灵片的制备方法及应用 | |
CN102641326B (zh) | 一种黄芪提取物及其制备和应用方法 | |
JP2010536804A (ja) | 血糖降下剤を調製するための、桑の枝由来のアルカロイドの有効画分の使用 | |
CN101612188B (zh) | 杜仲降压中药缓释制剂的制备方法及产品 | |
CN102134268B (zh) | 竹节参皂苷Ⅳa制备方法以及在制备保肝降酶药物中的应用 | |
US9453041B2 (en) | Method for preparing albiflorin and paeoniflorin | |
CN101618069B (zh) | 一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 | |
CN102805767B (zh) | 具有抗淋球菌作用的热淋清颗粒原料头花蓼提取物 | |
CN103565866A (zh) | 一种三七总皂苷的制备方法 | |
CN103764158B (zh) | 一种抗快速性心律失常的制剂及其制备方法 | |
CN101822762A (zh) | 一种用于治疗痛经的中药复方有效部位及其制备方法与应用 | |
CN101396373B (zh) | 一种华蟾素提取物及其制备方法 | |
CN103381200A (zh) | 一种桑白皮总生物碱提取物及其制备应用 | |
CN102988550B (zh) | 一种芩连片的制备方法及应用 | |
CN103800418A (zh) | 一种活血止痛组合物及胶囊制备工艺和应用 | |
CN103977391A (zh) | 一种小柴胡胶囊的制备方法及应用 | |
CN103393786A (zh) | 治疗哮喘病的药物及其制备方法 | |
CN102836381A (zh) | 一种安中片的制备方法及应用 | |
CN102988500B (zh) | 一种复方胆通片的制备方法及应用 | |
CN102670698B (zh) | 千斤拔提取物在制备防治糖尿病药物中的应用 | |
CN102631386B (zh) | 柴胡解热镇痛制剂及其制备工艺 | |
CN101375954B (zh) | 一种药物组合物、其制备方法及用途 | |
CN101744859B (zh) | 一种活血、祛瘀、止痛的药物组合物及其制备方法 | |
CN101322734A (zh) | 具有抗炎免疫作用的轮叶党参总皂苷及其制备方法 | |
CN103417644B (zh) | 一种黑骨藤复方提取物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: HENGKANG MEDICAL GROUP CO., LTD. Free format text: FORMER NAME: GANSU DUYIWEI BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 610063 Sichuan city of Chengdu province stone new idea Road Industrial Development Zone Jinjiang Road No. 456 Patentee after: HENGKANG MEDICAL GROUP CO.,LTD. Address before: 610063 Sichuan city of Chengdu province stone new idea Road Industrial Development Zone Jinjiang Road No. 456 Patentee before: GANSU DUYIWEI BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 746500 Gansu city of Longnan Province Wang Kang dam Duyiwei Industrial Park Patentee after: HENGKANG MEDICAL GROUP CO.,LTD. Address before: 610063 Sichuan city of Chengdu province stone new idea Road Industrial Development Zone Jinjiang Road No. 456 Patentee before: HENGKANG MEDICAL GROUP CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 746500 Wang Yi Industrial Park, Wang Ba, Kang County, Longnan, Gansu Patentee after: New Journey Health Technology Group Co.,Ltd. Address before: 746500 Wang Yi Industrial Park, Wang Ba, Kang County, Longnan, Gansu Patentee before: HENGKANG MEDICAL GROUP CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder |